首页> 外文OA文献 >Elevated IL‑6/IL‑1Ra ratio as a prognostic biomarker of poor chemotherapy efficacy in Chinese patients with metastatic NSCLC, validated in a Caucasian patient cohort

【2h】

Elevated IL‑6/IL‑1Ra ratio as a prognostic biomarker of poor chemotherapy efficacy in Chinese patients with metastatic NSCLC, validated in a Caucasian patient cohort

机译：IL-6 / IL-1RA比例作为中国转移NSCLC患者化疗疗效不良的预后生物标志物，在白种人患者队列中验证

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Fang Liu; Beno�t Sansas; Xavier Pr�ville; Romain Gineste; Jialei Wang; Hui Yu; Xia Meng; Romain Micol; Luc Barraud;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib [J] . Victor H. F. Lee, Dennis K. C. Leung, Tim-Shing Choy, BMC Cancer . 2016,第1期

机译：阿法替尼在中国EGFR突变转移性非小细胞肺癌（NSCLC）先前对第一代酪氨酸激酶抑制剂（TKI）和化疗有反应的中国患者中的疗效和安全性：与使用埃洛替尼的历史队列比较
2. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. [J] . Thom I, Andritzky B, Schuch G, Cancer: A Journal of the American Cancer Society . 2010,第17期

机译：YKL-40的预处理血药浓度升高，这是转移性非小细胞肺癌患者生存不良的独立预后生物标志物。
3. Elevated pretreatment serum concentration of YKL-40—An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer† [J] . Ina Thouml, m MD, Birte Andritzky MD, Cancer . 2010,第17期

机译：升高的治疗前血清YKL-40浓度是转移性非小细胞肺癌患者生存不良的独立预后生物标志物†
4. Correlation study of (IL-17 , IL-17RA ) and some biochemical parameters with patients of iraq colorectal cancer after and before taking a dose of chemotherapy [C] . Mezher N. Moslem, A. F. Altaie International Conference on Materials Engineering and Science . 2020

机译：（IL-17，IL-17RA）与一些生物化学参数与伊拉克结肠直肠癌患者服用化疗的相关性研究
5. Prognostic Biomarkers for Diffuse Large B Cell Lymphoma Patient Survival after Treatment with Chemotherapy: A Retrospective Analysis of 88 Cases [D] . Bushra, Hamama tul. 2019

机译：弥漫性大B细胞淋巴瘤化疗后患者生存的预后生物标志物：88例回顾性分析
6. Elevated IL-6/IL-1Ra ratio as a prognostic biomarker of poor chemotherapy efficacy in Chinese patients with metastatic NSCLC validated in a Caucasian patient cohort [O] . Fang Liu, Benoît Sansas, Xavier Préville, -1

机译：IL-6 / IL-1Ra比率升高是中国转移性NSCLC患者化疗效果较差的预后生物标志物在白种人患者队列中得到验证
7. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib [O] . 2016

机译：阿法替尼在中国EGFR突变转移性非小细胞肺癌（NSCLC）先前对第一代酪氨酸激酶抑制剂（TKI）和化疗有反应的中国患者中的疗效和安全性：与使用厄洛替尼的历史队列比较

Elevated IL‑6/IL‑1Ra ratio as a prognostic biomarker of poor chemotherapy efficacy in Chinese patients with metastatic NSCLC, validated in a Caucasian patient cohort

著录项

引文网络

相似文献

相关主题

期刊订阅